Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues. The drugmaker published a new five-year business plan on Monday ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · JP
- [CONFLICT] Japan developers warn of risk for new condo delays due to Iran war
- [CONFLICT] View from Tokyo: Has Iran war changed confidence in the US?
- [CONFLICT] Rise of Anthropic's Mythos spurs Japan to bolster cybersecurity on infrastructure
- [CONFLICT] From Ally to Target: How U.S. Tariffs on Europe, Japan, and Canada Are Fracturing the Western Alliance
- [FINANCE] Japanese Yen: Intervention Support And Rate Path Analysis From Rabobank - Bitcoin World
- [FINANCE] Japanese Yen: Choppy trade versus US Dollar around intervention line – OCBC - FXStreet